En Carta Diagnostics, a synthetic-biology biotech company focused on decentralizing highly reliable molecular diagnostic solutions, has secured $5.5M in a seed funding round. The investment will advance its patented technologies, designed to bring sophisticated diagnostics out of traditional labs and closer to patients.
The company's mission, "Diagnostics for Better care, Everywhere," underscores its commitment to expanding access to critical health insights. This capital infusion is set to accelerate the deployment of its innovative solutions, aiming to make advanced diagnostics universally available.
